Daptomycin Side Effects and Monitoring

Introduction to Daptomycin Side Effects

• The American College of Physicians and Infectious Diseases specialists recommend monitoring for elevated creatine phosphokinase (CPK) levels, muscle pain or weakness, rhabdomyolysis, and eosinophilic pneumonia during daptomycin treatment, with CPK elevation requiring regular monitoring, particularly at higher doses (≥6 mg/kg/day) 1, 2

Major Side Effects

Musculoskeletal Effects

• Elevated creatine phosphokinase (CPK) levels occur more frequently at higher doses (≥6 mg/kg/day) compared to lower doses (4 mg/kg/day), according to the Infectious Diseases Society of America 1
• Weekly CPK monitoring is recommended for all patients, with more frequent monitoring for those with renal insufficiency or on concurrent statin therapy, as suggested by the Clinical Infectious Diseases guidelines 1

Respiratory Effects

• Eosinophilic pneumonia has been documented in multiple case reports, and the American Thoracic Society recommends considering this condition when using daptomycin 1
• Daptomycin should not be used for non-hematogenous pneumonia as it is inactivated by pulmonary surfactant, according to the Infectious Diseases Society of America 1, 3

Risk Factors and Monitoring

Risk Factors for CPK Elevation

• Renal insufficiency increases the risk of muscle toxicity, and the National Kidney Foundation recommends careful monitoring in these patients 1
• Higher doses (>6 mg/kg/day) are associated with a greater risk of CPK elevation, as reported by the Clinical Infectious Diseases journal 1

Monitoring Recommendations

• Weekly CPK monitoring is recommended for all patients, according to the Clinical Infectious Diseases guidelines 1
• More frequent monitoring is recommended for patients with renal insufficiency, concomitant statin therapy, or higher doses of daptomycin (>6 mg/kg), as suggested by the Infectious Diseases Society of America 1

Special Considerations

• Daptomycin is pregnancy category B, and the American College of Obstetricians and Gynecologists recommends using it with caution in pregnant women 1

Daptomycin Re-exposure and CK Elevation Risk

Evidence for Re-exposure Safety

• Daptomycin-induced myopathy appears to be dose-dependent and duration-dependent, with higher doses (≥6 mg/kg/day) and longer treatment courses associated with increased risk, according to the Journal of Microbiology, Immunology and Infection 4, 5
• Higher doses (>6 mg/kg/day) carry greater risk than the 4-6 mg/kg range used in the first course, as reported by the Journal of Microbiology, Immunology and Infection 4, 5